Please use this identifier to cite or link to this item:
Title: Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: Results of a double-blind, randomized, placebo-controlled trial
Author(s): Smith, Graeme Drummond 
Author(s): Mitchell, S. A.
Mee, A. S.
Palmer, K. R.
Chapman, R. W.
Issue Date: 2002
Publisher: Wiley
Journal: Alimentary Pharmacology and Therapeutics 
Volume: 16
Issue: 6
Start page: 1187
End page: 1195
Background: Alverine citrate has been used in the treatment of irritable bowel syndrome for many years.

Aims: To compare the efficacy and safety of a new formulation of alverine citrate, a 120-mg capsule, with placebo given three times daily for 12 weeks.

Methods: One hundred and seven patients with irritable bowel syndrome were entered into this three-centre, double-blind, randomized, placebo-controlled, parallel group trial. The primary end-point was relief of abdominal pain indicated by improvement in the scores for severity and frequency. Secondary efficacy variables included scores for other clinical symptoms and for overall well-being.

Results: The severity and frequency of abdominal pain improved in 66% and 68% of patients treated with alverine citrate vs. 58% and 69% of the placebo group, but these differences were not significant. The mean percentage reduction in the scores for abdominal pain from baseline to the final assessment, although greater in the alverine citrate group (43.7%) compared with the placebo group (33.3%), was not statistically significant.

Conclusions: Alverine citrate is no better than placebo at relieving the symptoms of irritable bowel syndrome. Future trials should be designed to take into account the high and persistent placebo response seen in this condition.
DOI: 10.1046/j.1365-2036.2002.01277.x
CIHE Affiliated Publication: No
Appears in Collections:HS Publication

Files in This Item:
File Description SizeFormat
View Online135 BHTMLView/Open
SFX Query Show full item record

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.